Skip to main content
SpringerLink
Log in

The lipid research clinics coronary primary prevention trial: Design, results, and implications

  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The Coronary Primary Prevention Tiral (CPPT) was the major clinical investigation conducted in the Lipid Research Clinics (LRC) Program. There were 12 North American clinics involved in this joint double-blind protocol. The hypothesis tested was: lowering plasma cholesterol in middle-aged men with primary hypercholesterolemia [plasma total cholesterol greater than or equal to 265 mg/dl (6.88 mm/1)] who are otherwise healthy leads to a reduction in coronary heart disease (CHD) as manifest by a reduction in definite myocardial infarction (fatal and nonfatal) over a 7-year follow-up of all participants. The trial was conducted in 3806 male volunteers between the ages of 35 and 59, who were randomly assigned to two equal groups. The treatment group received a moderate cholesterol-lowering diet plus cholestyramine; the placebo group received an identical diet plus a placebo. The study medication was administered at 24 g daily in divided doses. The participants were followed up bimonthly for an average of 7.4 years. The diet (daily cholesterol intake of about 400 mg and a polyunsaturated fat/saturated fat ratio of 0.8) lowered plasma cholesterol by an average of 4%, as designed. The cholestyramine group experienced average plasma total cholesterol (TC) lowering and plasma low-density lipoprotein cholesterol (LDC-C) lowering 8.5% and 12.6% greater than the placebo group, respectively. This resulted in a 19% reduction in definite myocardial infarction (P < 0.05). The trial results for CHD deaths, nonfatal myocardial infarction, new positive exercise stress tests (P < 0.001) new-onset angina (P < 0.01) and coronary artery bypass surgery (P < 0.06) were consistent with and supportive of the main findings of the study. Total mortality also showed a slight decrease in the active treatment group, but the magnitude of the effect was reduced by a greater number of deaths from accidents and violence in the placebo group. The main findings of the study show that the reduction of plasma TC by lowering plasma LDL-C levels can diminish the incidence of CHD morbidity and mortality in men at high risk of CHD. A causal role for these lipids and lipoproteins in the pathogenesis of CHD is strongly suggested. The findings from this and other trials and epidemiologic studies suggest that for every 1 % reduction in TC there is a 2% reduction in risk of CHD. The study cohort remains in long-term follow-up.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Levy RI (1981) Review declining mortality in coronary heart disease. Arteriosclerosis 1: 312–325

    PubMed  Google Scholar 

  2. National Center for Health Statistics (1988) Annual summary of births, marriages, divorces and death: United States Government Printing Office Washington, DC

  3. Gordon T, Castelli WP, Hjortland MC, et al. (1977) The prediction of coronary heart disease by high-density and other lipoproteins. An historical perspective. In: Rifkind B, Levy R (eds) Hyperlipidemia — diagnosis and therapy. Grune & Stratton, New York, pp 71–78

    Google Scholar 

  4. Stamler J (1979) Population studies. In: Levy RI, Rifkind BM, Dennis BH, et al. (eds) (1979) Nutrition, lipids, and coronary heart disease. Raven Press, New York, pp 25–88

    Google Scholar 

  5. Arteriosclerosis (1971) A report by the National Heart and Lung Institute Task Force on Arteriosclerosis. (Dept of Health, Education, and Welfare (NIH) publication no 1). National Institutes of Health, Washington, DC, pp 72–137

  6. The Lipid Research Clinics Program (1979) The Coronary Primary Prevention Trial: design and implementation. J Chron Dis 32: 609–631

    Google Scholar 

  7. The Lipid Research Clinics Program (1983) Participant recruitment to the coronary primary prevention trial. J Chron Dis 36: 451–465

    Google Scholar 

  8. The Lipid Research Clinics Program (1983) Pre-entry characteristics of participants in the lipid research clinics coronary primary prevention trial. J Chron Dis 36: 467–479

    Google Scholar 

  9. Protocol for the Lipid Research Clinics Type II Coronary Primary Prevention Trial (1980) University of North Carolina Department of Biostatistics, Chapel Hill, NC

  10. Dennis B, Ernst N, Hjortland M, et al. (1980) The NHLBI nutrition data system. J Am Diet Assoc 77: 641–647

    PubMed  Google Scholar 

  11. Lippel K, Ahmed S, Albers JJ, et al. (1977) Analytical performance and comparability of the determination of cholesterol in 12 lipid research clinics. Clin Chem 23: 1744–1752

    PubMed  Google Scholar 

  12. Ahmed S, Lippel K, Bachorik PS, et al. (1978) Analytical performance and comparability of the determination of triglycerides by 12 lipid research clinics. Clin Chem 24: 330–338

    PubMed  Google Scholar 

  13. Hainline A Jr, Karon JM, Winn CL, Gill JB (1986) Accuracy and comparability of long-term measurements of cholesterol. Clin Chem 32: 611–615

    PubMed  Google Scholar 

  14. Lipid Research Clinics Program (1984) The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in incidence of coronary heart disease. JAMA 251: 351–364

    Google Scholar 

  15. Kronmal RA (1985) Commentary on the published results of the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 253: 2090–2093

    Google Scholar 

  16. The Lipid Research Clinics Program Investigators (1985) Reply to commentary by Richard Kronmal. JAMA 254: 263–264

    Google Scholar 

  17. Kalbfleisch JD, Prentice RL (1980) The statistical analysis of failure time data. Wiley, New York

    Google Scholar 

  18. O'Brien PC, Fleming TR (1979) A multiple testing procedure for clinical trials. Biometrics 35: 549–556

    PubMed  Google Scholar 

  19. Majundar H, Sen PK (1978) Nonparametric testing for simple linear regression under progressive censoring with staggering entry and random withdrawal. Communication in Statistics — Theory and Methods. A7: 349–371

    Google Scholar 

  20. Breslow N, Haug C (1972) Sequential comparison of exponential survival curves. J Am Star Assoc 67: 691–697

    Google Scholar 

  21. Lipid Research Clinics Program (1984) The Lipid Research Clinics Coronary Primary Prevention Trial Results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 254: 365–374

    Google Scholar 

  22. Davis CE, Havlik R (1977) Clinical trials of lipid lowering and coronary artery disease prevention. In: Rifkind BM, Levy RI (eds): Hyperlipidemia — diagnosis and therapy. Grune & Stratton, New York, pp 79–92

    Google Scholar 

  23. WHO Clofibrate Trial: Committee of Principal Investigators (1978) A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate, report. Br Heart J 40: 1069–1118

    Google Scholar 

  24. The Coronary Drug Project (1975) Clofibrate and niacin in coronary heart disease. JAMA 231: 360–381

    Google Scholar 

  25. Oliver MF (1981) Serum cholesterol: the knave of hearts and the joker. Lancet II: 1090–1095

    Google Scholar 

  26. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237–1245

    PubMed  Google Scholar 

  27. Virkkunen M (1985) Lipid Research Clinics Primary Prevention Trial Results. JAMA 253: 635–636

    Google Scholar 

  28. Pekkanen J, Nissinen A, Pusar S, Karvonen MJ (1989) Serum cholesterol and risk of accidental or violent death in a 25-year follow-up. Arch Intern Med 149: 1589–1591

    PubMed  Google Scholar 

  29. Gordon DJ, Knoke J, Probstfield JL, Superko R, Tyroller HA (1986) High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: The Lipid Research Clinics Coronary Primary Prevention Trial. Circulation 74: 1217–1225

    PubMed  Google Scholar 

  30. McGee D, Gordon T (1976) The results of the Framingham Study applied to four other U. S. based epidemiologic studies of cardiovascular disease. In: Kannel WB, Gordon T (eds) The Framingham Study: an epidemiologic investigation of cardiovascular disease. (Dept of Health, Education and Welfare publication (NIH) 76-1083) National Institutes of Health, Washington, DC

    Google Scholar 

  31. Keys A, Aravanis C, Blackburn H, et al. (1972) Probability of middle-aged men developing coronary heart disease in five years. Circulation 45: 815–828

    PubMed  Google Scholar 

  32. Mann JI, Marr JW (1981) Coronary heart disease prevention: trials of diets to control hyperlipidemia. In: Miller NE, Lewis B (eds) Lipoproteins, atherosclerosis and coronary heart disease. Elsevier/North-Holland Biomedical, Amsterdam, pp 197–210

    Google Scholar 

  33. Hunninghake DB, Probstfield JL (1977) Drug treatment of hyperlipoproteinemia. In: Rifkind BM, Levy RI (eds) Hyperlipidemia: diagnosis and therapy. Grune & Stratton, New York, pp 321–362

    Google Scholar 

  34. Hunninghake DB (1980) Drug interactions involving hypolipidemic drugs. In: Petrie JC (ed) Cardiovascular and respiratory disease therapy. Elseveir/North-Holland Biomedical, New York, pp 79–105

    Google Scholar 

  35. Hunninghake DB (1986) Resin therapy. Adverse effects and their management. In: Fears R (ed) Pharmacological control of hyperlipidemia. Prous Science, Barcelona, pp 67–89

    Google Scholar 

  36. Probstfield JL, Russell ML, Henske JC, Reardon RJ, Insull W (1986) Successful program for recovery of dropouts to a clinical trial. Am J Med 80: 777–784

    PubMed  Google Scholar 

  37. Cramer JA, Collins JF, Mattson RH (1988) Can categorization of patient background problems be used to determine early termination in a clinical trial? Controlled Clin Trials 9: 47–63

    PubMed  Google Scholar 

  38. Hunninghake DB (1982) Experience with individual lipid-lowering drugs: bile-acid sequestrants. Cardiovasc Rev Rep 3: 1184–1186

    Google Scholar 

  39. Peters JR, Hunninghake DB (1985) Effect of time of administration of cholestyramine on plasma lipids and lipoproteins Artery 13: 1–6

    PubMed  Google Scholar 

  40. The Expert Panel (1988) Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 148: 36–69

    Google Scholar 

  41. National Cholesterol Education Program (1988) High blood cholesterol in adults. Report of the Expert Panel on Detection, Evaluation and Treatment. (NIH Publication 88-2925) National Institutes of Health, Bethesda Md

    Google Scholar 

  42. Laboratory Standardization Panel (1988) Current status of blood cholesterol measurement in clinical laboratories in the United States: a report from the Laboratory Standardization Panel of the National Cholesterol Education Program. Clin Chem 34: 193–201

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Heart and Vascular Disease, Lipid Metabolism and Atherogenesis Branch, National Heart, Lung, and Blood Institute, USA

    J. L. Probstfield & B. M. Rifkind

  2. Clinical Trials Branch, DECA-NHLBI, Federal Building 5C-10, 7550 Wisconsin Avenue, 20892, Bethesda, MD, USA

    J. L. Probstfield

Authors
  1. J. L. Probstfield
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. M. Rifkind
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Probstfield, J.L., Rifkind, B.M. The lipid research clinics coronary primary prevention trial: Design, results, and implications. Eur J Clin Pharmacol 40, S69–S75 (1991). https://doi.org/10.1007/BF01409413

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01409413

Key words

Search

Navigation